CUREVAC NV (5CV.DE) Stock Fundamental Analysis
Europe - FRA:5CV - NL0015436031 - Common Stock
4.582 EUR
-0.03 (-0.61%)
Taking everything into account, 5CV scores 6 out of 10 in our fundamental rating. 5CV was compared to 81 industry peers in the Biotechnology industry. 5CV is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. 5CV is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
5CV had positive earnings in the past year.
In the past year 5CV had a positive cash flow from operations.
5CV had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: 5CV reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of 5CV (28.11%) is better than 92.59% of its industry peers.
5CV has a better Return On Equity (33.02%) than 95.06% of its industry peers.
5CV's Return On Invested Capital of 28.35% is amongst the best of the industry. 5CV outperforms 97.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.11% | ||
| ROE | 33.02% | ||
| ROIC | 28.35% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 37.93%, 5CV belongs to the best of the industry, outperforming 90.12% of the companies in the same industry.
5CV's Operating Margin of 40.58% is amongst the best of the industry. 5CV outperforms 95.06% of its industry peers.
5CV has a better Gross Margin (94.81%) than 88.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 40.58% | ||
| PM (TTM) | 37.93% | ||
| GM | 94.81% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
5CV has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
5CV has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for 5CV has been increased compared to 5 years ago.
5CV has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 9.52 indicates that 5CV is not in any danger for bankruptcy at the moment.
5CV has a better Altman-Z score (9.52) than 83.95% of its industry peers.
5CV has a debt to FCF ratio of 0.18. This is a very positive value and a sign of high solvency as it would only need 0.18 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.18, 5CV belongs to the top of the industry, outperforming 92.59% of the companies in the same industry.
A Debt/Equity ratio of 0.05 indicates that 5CV is not too dependend on debt financing.
5CV has a better Debt to Equity ratio (0.05) than 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.18 | ||
| Altman-Z | 9.52 |
ROIC/WACC3.93
WACC7.22%
2.3 Liquidity
A Current Ratio of 6.17 indicates that 5CV has no problem at all paying its short term obligations.
5CV's Current ratio of 6.17 is amongst the best of the industry. 5CV outperforms 83.95% of its industry peers.
5CV has a Quick Ratio of 6.16. This indicates that 5CV is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 6.16, 5CV belongs to the best of the industry, outperforming 83.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.17 | ||
| Quick Ratio | 6.16 |
3. Growth
3.1 Past
5CV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 170.16%, which is quite impressive.
5CV shows a strong growth in Revenue. In the last year, the Revenue has grown by 675.15%.
The Revenue has been growing by 98.42% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)170.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
Revenue 1Y (TTM)675.15%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-91.38%
3.2 Future
The Earnings Per Share is expected to decrease by -22.50% on average over the next years. This is quite bad
The Revenue is expected to decrease by -11.22% on average over the next years. This is quite bad
EPS Next Y-165.87%
EPS Next 2Y-62.26%
EPS Next 3Y-31.82%
EPS Next 5Y-22.5%
Revenue Next Year-86.8%
Revenue Next 2Y-59.56%
Revenue Next 3Y-30.81%
Revenue Next 5Y-11.22%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
5CV is valuated cheaply with a Price/Earnings ratio of 5.27.
93.83% of the companies in the same industry are more expensive than 5CV, based on the Price/Earnings ratio.
5CV's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.40.
The Forward Price/Earnings Ratio is negative for 5CV. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.27 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 5CV indicates a rather cheap valuation: 5CV is cheaper than 95.06% of the companies listed in the same industry.
95.06% of the companies in the same industry are more expensive than 5CV, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.26 | ||
| EV/EBITDA | 2.97 |
4.3 Compensation for Growth
The decent profitability rating of 5CV may justify a higher PE ratio.
5CV's earnings are expected to decrease with -31.82% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-62.26%
EPS Next 3Y-31.82%
5. Dividend
5.1 Amount
No dividends for 5CV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:5CV (10/17/2025, 7:00:00 PM)
4.582
-0.03 (-0.61%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners6.53%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap1.03B
Analysts72.31
Price Target4.19 (-8.56%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-29.18%
Min EPS beat(2)-39.67%
Max EPS beat(2)-18.68%
EPS beat(4)2
Avg EPS beat(4)34.62%
Min EPS beat(4)-39.67%
Max EPS beat(4)161.44%
EPS beat(8)3
Avg EPS beat(8)-1.81%
EPS beat(12)5
Avg EPS beat(12)-8.17%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-91.68%
Min Revenue beat(2)-96.47%
Max Revenue beat(2)-86.88%
Revenue beat(4)2
Avg Revenue beat(4)75.38%
Min Revenue beat(4)-96.47%
Max Revenue beat(4)366.65%
Revenue beat(8)4
Avg Revenue beat(8)53.09%
Revenue beat(12)4
Avg Revenue beat(12)21.18%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.19%
PT rev (3m)2.24%
EPS NQ rev (1m)-275%
EPS NQ rev (3m)-275%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)220.62%
Revenue NQ rev (3m)220.62%
Revenue NY rev (1m)-14.11%
Revenue NY rev (3m)-14.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.27 | ||
| Fwd PE | N/A | ||
| P/S | 2.02 | ||
| P/FCF | 5.26 | ||
| P/OCF | 5.06 | ||
| P/B | 1.76 | ||
| P/tB | 1.84 | ||
| EV/EBITDA | 2.97 |
EPS(TTM)0.87
EY18.99%
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)0.87
FCFY19.01%
OCF(TTM)0.91
OCFY19.78%
SpS2.27
BVpS2.6
TBVpS2.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.11% | ||
| ROE | 33.02% | ||
| ROCE | 33.37% | ||
| ROIC | 28.35% | ||
| ROICexc | 78.22% | ||
| ROICexgc | 88.03% | ||
| OM | 40.58% | ||
| PM (TTM) | 37.93% | ||
| GM | 94.81% | ||
| FCFM | 38.42% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score9
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.18 | ||
| Debt/EBITDA | 0.14 | ||
| Cap/Depr | 44.58% | ||
| Cap/Sales | 1.55% | ||
| Interest Coverage | 91.31 | ||
| Cash Conversion | 90.71% | ||
| Profit Quality | 101.3% | ||
| Current Ratio | 6.17 | ||
| Quick Ratio | 6.16 | ||
| Altman-Z | 9.52 |
F-Score9
WACC7.22%
ROIC/WACC3.93
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)170.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
EPS Next Y-165.87%
EPS Next 2Y-62.26%
EPS Next 3Y-31.82%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)675.15%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-91.38%
Revenue Next Year-86.8%
Revenue Next 2Y-59.56%
Revenue Next 3Y-30.81%
Revenue Next 5Y-11.22%
EBIT growth 1Y171.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-152.22%
EBIT Next 3Y-32.99%
EBIT Next 5Y10.78%
FCF growth 1Y160.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y182.06%
OCF growth 3YN/A
OCF growth 5YN/A